Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a higher discontinuation rate due to adverse effects, including gastrointestinal issues and skin sensations. Detailed data will be presented at the American Diabetes Association conference in June. This development poses a significant competitive threat to Novo Nordisk's dominant position in the obesity drug market.
Eli Lilly reported positive Phase 3 trial results for retatrutide, a triple hormone drug targeting obesity. Patients on the highest 12 mg dose lost an average of 28.3% of their body weight, with significant improvements in cardiovascular risk markers...
Eli Lilly announced it will present important clinical trial data at the 2026 ASCO Annual Meeting, including Phase 3 results for Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive non-small cell lung cancer and Verzenio (abemaciclib) ...
Eli Lilly reported a 55.5% revenue increase in Q1 2026, driven by strong sales of Mounjaro and Zepbound. Despite this growth and raised full-year guidance, shares have fallen due to pricing pressures from China and the U.S., and competition from Novo...
Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage trial, with patients losing up to 28.3% of their body weight over 80 weeks. The drug, which targets three gut hormones, outperformed existing trea...
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
